Fundraising Fox
Naveris
Waltham, US · Founded 2017 · Delaware corporation · 3 known investors
Find your way into Naveris
Sign up to see every warm intro you have to Naveris
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Naveris team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Naveris develops and commercializes liquid biopsy tests for the early detection and monitoring of HPV-associated cancers, particularly head and neck and anal cancers. The company's flagship NavDx test uses proprietary technology to detect tumor tissue-modified viral HPV DNA in blood plasma, offering high sensitivity and specificity for cancer surveillance.
Founders & leadership
Board
Investors · 3
How we know: barchart.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · barchart.com · Not right? Tell us
Funding
SEC filings, press & company announcements$67M disclosed across 4 of 5 rounds · 2019–2024
- $33.4MSeries ASep 2022 · 3 sources
Gurnet Point Capital (lead), BrightEdge, TechU Ventures
Source ↗
▶$17.5MraisedJul 2024 · 5 investors · BiotechnologyRule 506(b)
- James McNallyExecutive Officer, Director
- Anne StoneDirector
- Francis CrispinoDirector
- Piyush GuptaExecutive Officer, Director
- Offering amount
- $27.2M
- Amount sold
- $17.5M
- Sales commissions
- $1.8M
- Placement agents
- Cowen and Company, LLC
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.4MraisedMar 2020 · 21 investors · BiotechnologyRule 506(b)
- Piyush GuptaExecutive Officer, Director
- Philip StephensExecutive Officer
- Barry BergerDirector
- Sophie KornowskiDirector
- Offering amount
- $17M
- Amount sold
- $15.4M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$650KraisedSep 2019 · 3 investors · Other TechnologyRule 506(b)
- Philip Grahame HaydonDirector
- Piyush GuptaExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $650K
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Naveris.
In the news
Frequently asked questions
- What does Naveris do?
- Naveris develops and commercializes liquid biopsy tests for the early detection and monitoring of HPV-associated cancers, particularly head and neck and anal cancers. The company's flagship NavDx test uses proprietary technology to detect tumor tissue-modified viral HPV DNA in blood plasma, offering high sensitivity and specificity for cancer surveillance.
- Who are Naveris's investors?
- Naveris's investors include BrightEdge, Gurnet Point Capital, TechU Ventures.
- How much funding has Naveris raised?
- Naveris has disclosed $67M raised across 4 of its 5 known rounds.
- Where is Naveris headquartered?
- Naveris is headquartered in Waltham, US.